Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Launched by STANFORD UNIVERSITY · Jul 16, 2015

Keywords

ClinConnect Summary

This clinical trial is studying the use of low-dose naltrexone (LDN) as a potential treatment for Complex Regional Pain Syndrome (CRPS), a condition that causes ongoing pain, usually in the arms or legs. The goal is to see if LDN can help relieve the symptoms of this condition. Participants in the study will be randomly assigned to receive either LDN or a placebo (a substance with no active medication) for several weeks. Throughout this time, they will attend in-person or virtual visits and complete questionnaires about their experiences.

To be eligible for the study, participants should be between 18 and 75 years old and have been diagnosed with CRPS for at least a year. They should also be on stable pain treatment for at least a month before joining the trial. However, individuals with known allergies to naltrexone, those currently using prescription opioid painkillers, or those who are pregnant (or planning to become pregnant) cannot participate. If you or someone you know might be interested in joining this study, it could be a good opportunity to explore a new treatment option for managing CRPS symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Upper and/or lower extremity CRPS
• • On stable treatment for 1 month
• • CRPS for at least 1 year
• • Meet the Budapest criteria for CRPS at time of the study.
• Exclusion Criteria:
• • Any known allergy to naltrexone or naloxone
• • Use of prescription opioid analgesics or illegal opioid use
• • Current or planned pregnancy.